Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.31 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.31 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.31 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.31 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.31 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.31 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.31 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.31 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.31 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.31 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.31 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL471896 | 1.00 | PAOX (0.37) | PAOXBLMNPSR1POLBLMNA | |
| SCHEMBL116656 | 0.98 | PAOX (0.38) | PAOXBLMNPSR1POLBLMNA | |
| SCHEMBL230134 | 0.98 | PAOX (0.38) | PAOXBLMNPSR1POLBLMNA | |
| Trimethylammonium SCHEMBL27922389 | 0.92 | PAOX (0.34) | PAOX | |
| SCHEMBL6530955 | 0.91 | PAOX (0.41) | PAOXBLMNPSR1POLBLMNA | |
| SCHEMBL16353965 | 0.89 | PAOX (0.45) | PAOXLMNACYP1A2THRBKMT2A | |
| SCHEMBL16353966 | 0.89 | PAOX (0.45) | PAOXLMNACYP1A2THRBKMT2A | |
| SCHEMBL3508075 | 0.89 | PAOX (0.45) | PAOXLMNACYP1A2THRBKMT2A | |
| SCHEMBL3675645 | 0.89 | PAOX (0.45) | PAOXLMNACYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL2357233 | 0.86 | POLB (0.33) | PAOXBLMPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120078958-A | Biophysical and biochemical dual-gradient bionic hydrogel, preparation and application thereof in promoting bone cartilage regeneration | 北京大学国际医院 | 2025-06-03 | — | — | CN | claimed |
| CN-103204784-B | Synthesis method for N-(3-aminopropyl) methacrylamide hydrochloride | GANSU KERUI BIOLOG SCIENCE & TECHNOLOGY CO LTD | 2015-06-10 | — | — | CN | claimed |
| EP-0213896-B1 | ADHESION PROMOTING POLYMERIC MATERIALS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1992-01-22 | — | — | EP | claimed |
| EP-0213896-A2 | Adhesion promoting polymeric materials | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-03-11 | — | — | EP | claimed |
| US-20260115717-A1 | SYSTEM AND METHOD FOR MONITORING ANALYTES WITHIN BLOOD, BODILY FLUIDS, OR TISSUE OF A PATIENT | CloverSense LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4714526-A1 | GAS RECOVERY DEVICE AND GAS RECOVERY METHOD | JCCL, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714527-A1 | GAS RECOVERY DEVICE AND GAS RECOVERY METHOD | JCCL, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-4688248-A2 | COMPOSITE PARTICLES | University of Leicester (GB) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025245320-A1 | SORBENT CONTACTOR FOR CARBON DIOXIDE CAPTURE FROM WATER | UT-BATTELLE, LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12447228-B2 | Polymer particles | TERUMO CORPORATION (JP) | 2025-10-21 | — | — | US | disclosed |
| CN-120132815-A | Preparation method of modified membrane material and application of modified membrane material in water treatment | 山东国灏建设投资有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120078958-A | Biophysical and biochemical dual-gradient bionic hydrogel, preparation and application thereof in promoting bone cartilage regeneration | 北京大学国际医院 | 2025-06-03 | — | — | CN | disclosed |
| WO-1993025587-A1 | FUNCTIONALISATION OF POLYMERS | THE UNIVERSITY OF LIVERPOOL (GB) | 1993-12-23 | — | — | WO | disclosed |
| US-5254441-A | Barrier polymer layer of hydrophobic and ionic hydrophilic unsaturated monomers | EASTMAN KODAK COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5244763-A | Hydrophilic colloid layer, reducing agent comprising polymer with gallic acid or gallic acid derivative moieties | EASTMAN KODAK COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0539729-A1 | Development inhibitor reflector layers | EASTMAN KODAK COMPANY (US) | 1993-05-05 | — | — | EP | disclosed |
| US-5198517-A | Reducing agents | EASTMAN KODAK COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| WO-1993003421-A1 | POLYMERIC SCAVENGERS FOR OXIDIZED DEVELOPING AGENTS AND PHOTOGRAPHIC ELEMENTS CONTAINING THE SAME | EASTMAN KODAK COMPANY (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0476117-A1 | THERMOREVERSIBLE HEAT-THICKENING POLYACRYLAMIDES. | EASTMAN KODAK CO (US) | 1992-03-25 | — | — | EP | disclosed |
| WO-1991015526-A2 | THERMOREVERSIBLE HEAT-THICKENING POLYACRYLAMIDES | EASTMAN KODAK COMPANY (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447228-B2 | Polymer particles | PCBP1, LCP1, PSAP | GABRP 1590/4885GABRD 3322/4885HDAC3 2035/4885 |
| US-20260115717-A1 | SYSTEM AND METHOD FOR MONITORING ANALYTES WITHIN BLOOD, BODILY FLUIDS, OR TISSUE OF A PATIENT | TNNI3, TNNC1, MB | GABRP 4673/4885GABRD 4229/4885HDAC3 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.